1 / 50

De-mystifying Outpatient Pulmonary Function Tests (PFTs)

De-mystifying Outpatient Pulmonary Function Tests (PFTs). Mani S. Kavuru, MD Professor & Division Chief Pulmonary & Critical Care Medicine Thomas Jefferson University / Hospital (No Disclosures). Key learning Objectives. Consider the concept of spirometry in the primary care setting;

tawana
Download Presentation

De-mystifying Outpatient Pulmonary Function Tests (PFTs)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. De-mystifying Outpatient Pulmonary Function Tests (PFTs) Mani S. Kavuru, MD Professor & Division Chief Pulmonary & Critical Care Medicine Thomas Jefferson University / Hospital (No Disclosures)

  2. Key learning Objectives • Consider the concept of spirometry in the primary care setting; • Review the spirometric maneuver, common patterns, concept of normality; • Discuss spirometry in the approach to lung disease; • Briefly review utility of other pulmonary function measures

  3. Office Spirometry:Outline • Why do you need it in PCP offices? Utility in screening, smoking cessation • What is spirometry? Basics of technique, interpretation, etc. Office vs. Diagnostic (in labs) • Who could / should perform it? Training, quality control issues • Challenges, controversies?

  4. Morbidity and Mortality of COPD • COPD is the 4th leading cause of death • Half the patients die within 10 years of diagnosis • 100,000 deaths/year in the U.S. • $13 billion/year in direct medical costs

  5. The Lung Health Study Preliminary Results: • 10 Participating Centers • Patient Demographics • 5,887 current smokers enrolled • Age 35-59 (mean 48.5 ± 6.8 years) • FEV1/FVC 63% ± 5.5 • 63% men, 37% women • 96% white Tashkin DP, et al. Am Rev Respir Dis. 1992; 145 (2 pt) 1):301-10.

  6. John Hutchinson (1811 – 1861)

  7. References • ATS/ERS position statements; • Books: Miller, Scacci, Gast: Lab Evaluation of Pulmonary Function; Clausen; others • Jefferson interpretation statements; CCF Disease Management document;

  8. Pulmonary Function Tests • Spirogram, +/- BDs • Lung volumes • Diffusing capacity • ABGs, 6 minute walk • Bronchoprovocation testing (i.e. mecolyl) • Cardiopulmonary exercise testing

  9. HOW: Standardized Testing • Spirometry using ATS & AARC standards • Patient sitting in chair with arms • Use nose-clips! (O2 disconnected) • Reproducible tests, 3 valid efforts min. • No cough in first second • Back extrapolation guidelines (good start) • Good peak flow effort • Exhalation 6 seconds or >1 second plateau

  10. Test Reproducibility

  11. Non-Reproducible

  12. Poor Start of Test

  13. Normal Spirometry : Variable Effort

  14. Glottic Closure : Cough

  15. Mild Obstruction : Severe Obstruction

  16. Restriction : Variable Intrathoracic

  17. Variable Extrathoracic : FixedUpper Airway Obstruction

  18. Reference Standards

  19. Spirometric Reference Values From a Sample of the U.S. Population (NHANES III) • Age 8-80 (N=7,429), asympt. non-smokers, ’88 – ’94 • ATS criteria met (’87, ’94), QA by NIOSH • Caucasians, African-Americans, Mex-Am • Age, standing Ht > weight , BMI • FVC, FEV1, FEV6, PEF, FEF25 – 75 Hankinson. AJRCCM 1999;159:179-187

  20. Spirometry • Two main measurements: • total volume exhaled (FVC) • lung/thorax expansion • HPP, IPF - restrictive lung diseases • volume exhaled in 1st second of exhalation (FEV1) • airway diameter • obstructive lung diseases • asthma, emphysema, chronic bronchitis, etc.

  21. Classification of Lung Diseases • Obstructive Disease: asthma; chronic bronchitis; emphysema; CF; • Restriction--Intra-parenchymal disease (lung tissue is abnormal, e.g. HP, pulmonary fibrosis) • Restriction--Extra-parenchymal disease (lung tissue is normal); chest wall deformities, kyphosis, scoliosis, obesity, pleural effusions, ascites • Neuromuscular disorders (“bellows”)

  22. Criticism of FEF 25-75% and Other Tests of Small Airway Disease FEF 25-75% • Does not detect small airway disease. • Is volume dependent. • Is affected by elastic recoil, small airways dysfunction and large airways dysfunction. • Is more variable than FEV1, but not as sensitive as FEV1/FVC%.

  23. Spirometry Spirometry provides an objective measurement of lung function Measures VOLUME; the amount of air a person can breath in (inhale); and breathe out (exhale) And the SPEED or FLOW RATE that is generated during that maneuver; Into a device called a Spirometer

More Related